Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L’Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025.
L’Oréal was selling 29,556,650 shares at €101.50 each, meaning its stake in Sanofi will decrease from 9.4% to 7.2%. Both listed in Paris, L’Oréal opened 2.5% lower on 3 February following the announcement whilst Sanofi opened 0.4% down.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The cosmetics company has held shares in Sanofi since 1999 and received $431m in dividends from the drugmaker in 2022 alone.
The transaction of shares represents a 2.8% discount on where Sanofi’s shares closed on 31 January. The pharma company’s shares have been flying high after raising its full-year profit outlook propelled by blockbuster asthma drug Dupixent (dupilumab) and new launches such as respiratory syncytial virus (RSV) vaccine Beyfortus (nirsevimab), developed as part of a partnership with AstraZeneca.
Whilst revealing its Q4 2024 results, Sanofi said it is planning to execute a $5.12bn share buyback programme in 2025. As of June 2024, Sanofi’s stakeholder structure comprised 67% owned by non-French institutional investors and 10.8% owned by French institutions. Individual shareholders and employees amounted to 5.3% and 2.6% of the drugmaker respectively. At the time, L’Oréal held 9.4%, with the remaining shares either unassigned or held via ‘miscellaneous’ buyers.
Sanofi’s chief financial officer François Roger said: “This transaction highlights Sanofi’s dedication to sustainable value creation while upholding our strategic priorities and preserving the strength of our key partnerships.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSanofi is in the process of transitioning into a pure vaccine and drug manufacturer as the company edges closer to closing a deal that would see it sell a controlling stake in its consumer health company Opella. In October 2024, Sanofi entered talks with US private equity company Clayton Dubilier & Rice (CD&R) over the sale of Opella, valued at around $17bn. A deal is slated to be completed by Q2 this year.
The share buyback comes nearly a week after Robert F Kennedy Jr was questioned on his anti-vaccine stance by senators ahead of potentially heading up the US Health and Human Services (HHS). Sanofi was one of many vaccine manufacturers whose shares took a temporary hit when he was announced as the nominee for the position by President Donald Trump late last year.
Sanofi is not the only big pharma company targeting a share buyback campaign. On the back of booming popularity for diabetes and weight loss treatments, Eli Lilly plans to buy back around $15bn in shares, as announced in December 2024. Buying back stock is a way for companies with auxiliary cash to boost earnings per share. It also increases the value of remaining shares and adjusts voting rights.
